Newron Pharmaceuticals S.p.A reported a fall in revenue and a widening of its annual operating loss in 2014 as it prepared to bring its first product to market – an add-on treatment for mid-to-late stage Parkinson’s disease. ---Subscribe to MedNous to access this article--- Company News
